Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes)

The CLEAR Outcomes trial randomized 13,970 statin-intolerant patients with established cardiovascular disease or high-risk primary prevention to bempedoic acid 180 mg daily or placebo and followed them for a median of 40 months.

Bempedoic acid reduced LDL-C by approximately 21% versus placebo and significantly reduced the primary endpoint of major adverse cardiovascular events (MACE-4: cardiovascular death, nonfatal MI, nonfatal stroke, or coronary revascularization) by 13% relative risk reduction (11.7% vs. 13.3%, HR 0.87). The absolute risk reduction was modest: 1.6 percentage points over 40 months. Individual components showed reduction driven primarily by nonfatal MI and coronary revascularization; cardiovascular death and stroke were not individually significant.

The clinical significance is specifically for statin-intolerant patients. Bempedoic acid fills a gap for patients who cannot tolerate statins, ezetimibe alone is insufficient, and the cost or access to PCSK9 inhibitors is a barrier. It is not a competitor to statins — its LDL-lowering is substantially less than high-intensity statin therapy — but it provides an option where none previously existed with proven cardiovascular endpoint data.

The gout risk increase (observed in CLEAR Outcomes) deserves attention in patients with pre-existing hyperuricemia.

We rate the evidence strong. A well-powered outcomes trial establishing bempedoic acid as an effective LDL-lowering option with clinical event reduction in statin-intolerant patients — important for a population with limited alternatives.